Alpha 2.0
Login Register
» Articles » PMID: 25601422

Oral Erythromycin Therapy in Epidermolysis Bullosa Simplex Generalized Severe

Overview
Journal Br J Dermatol
Publisher Oxford University Press
Specialty Dermatology
Date 2015 Jan 21
PMID 25601422
Citations 4
Authors
C Chiaverini
E Fontas
P Vabres
D Bessis
J Mazereeuw
A Charlesworth
G Meneguzzi
J-P Lacour
Affiliations
Soon will be listed here.
Citing Articles

A Novel Mutation p.L461P in Causing Localized Epidermolysis Bullosa Simplex.

Jiang X, Zhu Y, Sun H, Gu F Ann Dermatol. 2021; 33(1):11-17.

PMID: 33911807 PMC: 7875216. DOI: 10.5021/ad.2021.33.1.11.

Small molecule drug development for rare genodermatoses - evaluation of the current status in epidermolysis bullosa.

Wally V, Reisenberger M, Kitzmuller S, Laimer M Orphanet J Rare Dis. 2020; 15(1):292.

PMID: 33076941 PMC: 7574495. DOI: 10.1186/s13023-020-01467-9.

Basal pharmacokinetic parameters of topically applied diacerein in pediatric patients with generalized severe epidermolysis bullosa simplex.

Ablinger M, Felder T, Wimmer M, Zauner R, Hofbauer P, Lettner T Orphanet J Rare Dis. 2018; 13(1):193.

PMID: 30382914 PMC: 6211505. DOI: 10.1186/s13023-018-0940-1.

Cut and Paste: Efficient Homology-Directed Repair of a Dominant Negative KRT14 Mutation via CRISPR/Cas9 Nickases.

Kocher T, Peking P, Klausegger A, Murauer E, Hofbauer J, Wally V Mol Ther. 2017; 25(11):2585-2598.

PMID: 28888469 PMC: 5675592. DOI: 10.1016/j.ymthe.2017.08.015.